文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

妊娠期1型糖尿病闭环胰岛素输注:CIRCUIT随机临床试验

Closed-Loop Insulin Delivery in Type 1 Diabetes in Pregnancy: The CIRCUIT Randomized Clinical Trial.
PubMed 文献 · JAMA · 2025-01-01

CIRCUIT为开放标签随机试验,在加拿大和澳大利亚14个中心纳入妊娠14周前的1型糖尿病孕妇,随机分至闭环系统组(n=46)或标准照护组(n=45),主要结局为16至34周妊娠特异性血糖范围(63-140 mg/dL)时间百分比。闭环组该百分比为65.4%,标准照护组为50.3%,校正后平均差异12.5个百分点(95%CI 9.5-15.6;P<.001)。

要点

  • 闭环组妊娠特异性血糖范围时间百分比65.4%,标准照护组50.3%,校正后平均差异12.5个百分点(95%CI 9.5-15.6;P<.001)。
  • 闭环组发生1例严重低血糖,闭环组发生2例糖尿病酮症酸中毒,标准照护组发生1例。
  • 作者结论支持在1型糖尿病孕妇中使用该闭环系统。

核心结论

  • 使用闭环系统的1型糖尿病孕妇处于妊娠特异性血糖范围的时间显著多于接受标准照护者。
  • 这些发现支持在1型糖尿病孕妇中使用该闭环系统。

研究设计与样本

  • 开放标签随机临床试验,在加拿大和澳大利亚14个临床中心纳入妊娠14周前的1型糖尿病孕妇,随访至产后6周。
  • 2021年6月至2024年7月入组,2025年3月完成随访;94例入组者中3例在随机化前妊娠丢失,91例随机化(平均年龄31.7岁[SD 5.2];孕早期血红蛋白A1c 7.4%[SD 1.0%]),88例纳入主要分析。
  • 参与者按1:1随机分至闭环治疗组(n=46)或标准照护组(胰岛素泵或每日多次胰岛素注射)(n=45),均使用连续血糖监测。
  • 主要结局为16至34周妊娠期间通过连续血糖监测测量的妊娠特异性血糖范围(63-140 mg/dL)时间百分比。

主要发现

  • 16至34周妊娠期间妊娠特异性血糖范围平均时间百分比:闭环组65.4% vs 标准照护组50.3%(校正后平均差异12.5个百分点[95%CI 9.5-15.6];P<.001)。
  • 闭环组发生1例严重低血糖。
  • 闭环组发生2例糖尿病酮症酸中毒,标准照护组发生1例。

关键数值与推荐

  • 主要结局指标为妊娠特异性血糖范围(63-140 mg/dL)时间百分比,测量时段为16至34周妊娠。

临床怎么用

  • 作者结论支持在1型糖尿病孕妇中使用该闭环系统。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Hyperglycemia-related pregnancy complications occur in 50% of pregnant women with type 1 diabetes. Closed-loop insulin systems improve glycemia outside of pregnancy but have had limited testing in pregnancy. OBJECTIVE: To assess the efficacy of a closed-loop system in pregnancy. DESIGN, SETTING, AND PARTICIPANTS: Open-label trial enrolling pregnant women with type 1 diabetes at 14 clinical centers in Canada and Australia before 14 weeks' gestation with follow-up until 6 weeks postpartum. Enrollment occurred between June 2021 and July 2024 and follow-up was completed in March 2025. INTERVENTIONS: Participants were randomized 1:1 to closed-loop therapy (n = 46) or standard care (insulin pump or multiple daily insulin injections) (n = 45) with continuous glucose monitoring. MAIN OUTCOMES AND MEASURES: The primary outcome was the percentage of time spent in the pregnancy-specific glucose range (63-140 mg/dL), measured by continuous glucose monitoring from 16 to 34 weeks' gestation. RESULTS: Among 94 enrolled participants, 3 experienced pregnancy loss prior to randomization, 91 were randomized (mean age, 31.7 [SD, 5.2] years; early pregnancy hemoglobin A1c, 7.4% [SD, 1.0%]), and 88 were included in the primary analysis. The mean percentage of time spent in the pregnancy-specific glucose range from 16 to 34 weeks' gestation was 65.4% in the closed-loop group and 50.3% in the standard care group (mean adjusted difference, 12.5 [95% CI, 9.5-15.6] percentage points; P < .001). There was 1 episode of severe hypoglycemia in the closed-loop group, and there were 2 episodes of diabetic ketoacidosis in the closed-loop group and 1 in the standard care group. CONCLUSION AND RELEVANCE: Pregnant women with type 1 diabetes using a closed-loop system spent significantly more time in the pregnancy-specific glucose range than those receiving standard care. These findings support the use of this closed-loop system in pregnant women with type 1 diabetes. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04902378.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Donovan LE, Lemieux P, Dunlop AD, et al. Closed-Loop Insulin Delivery in Type 1 Diabetes in Pregnancy: The CIRCUIT Randomized Clinical Trial. JAMA. 2025. PMID: 41134589. doi:10.1001/jama.2025.19578

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。